These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 29727332)

  • 21. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
    Pietrantonio F; Miceli R; Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Morano F; Wotherspoon A; Valeri N; Kook MC; An JY; Grabsch HI; Fucà G; Noh SH; Sohn TS; Kim S; Di Bartolomeo M; Cunningham D; Lee J; Cheong JH; Smyth EC
    J Clin Oncol; 2019 Dec; 37(35):3392-3400. PubMed ID: 31513484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
    Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
    Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
    An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
    Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
    Dunne PD; McArt DG; O'Reilly PG; Coleman HG; Allen WL; Loughrey M; Van Schaeybroeck S; McDade S; Salto-Tellez M; Longley DB; Lawler M; Johnston PG
    Cancer Immunol Res; 2016 Jul; 4(7):582-91. PubMed ID: 27197062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses.
    Kim SY; Choi YY; An JY; Shin HB; Jo A; Choi H; Seo SH; Bang HJ; Cheong JH; Hyung WJ; Noh SH
    Int J Cancer; 2015 Aug; 137(4):819-25. PubMed ID: 25614197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
    Kim JW; Im SA; Kim MA; Cho HJ; Lee DW; Lee KH; Kim TY; Han SW; Oh DY; Lee HJ; Kim TY; Yang HK; Kim WH; Bang YJ
    Int J Cancer; 2014 Jan; 134(1):72-80. PubMed ID: 23649938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of microsatellite instability in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Cardili L; Dias AR; Alves VAF; de Mello ES; Ribeiro U
    J Gastrointest Surg; 2024 Oct; 28(10):1687-1695. PubMed ID: 39147611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.
    An JY; Kim H; Cheong JH; Hyung WJ; Kim H; Noh SH
    Int J Cancer; 2012 Jul; 131(2):505-11. PubMed ID: 21898388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study.
    Oh N; Kim H; Kim KM; Cheong JH; Lee J; Noh SH; Sohn TS; Choi YY; An JY
    Ann Surg Oncol; 2021 Dec; 28(13):8908-8915. PubMed ID: 34401986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma.
    Klose J; Lasitschka F; Horsch C; Strowitzki MJ; Bruckner T; Volz C; Schmidt T; Schneider M
    Scand J Gastroenterol; 2020 Mar; 55(3):321-329. PubMed ID: 32191146
    [No Abstract]   [Full Text] [Related]  

  • 39. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.